Company intelligence / Profile preview

Lipid Therapeutics GmbH

Heidelberg, Baden-Württemberg, Germany

Ownership: Private
Development stage: Phase 3

Overview

LT-02, a delayed release formulation of Phosphatidylcholine, was designed as an add-on therapy to 5-aminosalicylic acid to improve the barrier function of the mucosal layer of the colon for ulcerative colitis treatment

Therapeutic areas: Gastroenterology
Modalities: PhospholipidsPhosphatidylcholine
Industry: Biotech

Drug pipeline

1 asset

phosphatidylcholine (LT-02)

Discontinued

Partnerships

Nestlé Health Science

Beyond the preview

Go deeper on Lipid Therapeutics GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lipid Therapeutics GmbH.

Explore the full profile